You are comparing two product listings. One cranberry capsule shows 100,000 mg across the front, while a D-mannose powder lists its serving in grams. At first glance, the larger number looks like the stronger choice.
That is the wrong scorecard. The cranberry figure may describe a fresh-fruit equivalent, while the D-mannose figure describes an amount of a different ingredient. These units do not compete. A useful comparison starts with ingredient identity, human evidence, what the label genuinely proves and whether a symptom, medicine or health factor overrides the shopping decision.
Direct answer: Cranberry and D-mannose are different ingredients, so their label amounts cannot be compared directly. Cranberry has systematic-review evidence suggesting it probably reduces symptomatic, culture-confirmed UTIs in some groups, including women with recurrent UTIs. In contrast, a large 2024 primary-care trial found no significant preventive benefit from daily D-mannose in women with recurrent UTIs. Neither cranberry nor D-mannose treats an active infection.
Two ingredients, two different identities
Cranberry: a fruit-derived ingredient with variable formulations
Cranberry is a fruit-derived ingredient, commonly from Vaccinium macrocarpon. Supplements may use juice, whole-fruit powder or concentrated extract. These formats can differ in composition, processing and the information shown on the label.
Cranberry contains plant compounds called proanthocyanidins, usually shortened to PACs. PACs have been studied in relation to bacterial adhesion, but different cranberry products should not automatically be treated as interchangeable. A juice, powder and concentrated extract can carry very different label information.
D-mannose: a simple sugar sold as powder or capsules
D-mannose is a simple sugar related to glucose. It is commonly sold as a powder or in capsules, with the amount usually stated per serving.
Its proposed urinary-support action is also often described through bacterial adhesion. That explanation may sound persuasive, but a plausible mechanism does not establish that people will have fewer clinically meaningful UTIs.
Use a mechanism-to-evidence ladder
When supplement claims sound convincing, work through four levels in order.
- Level 1: Ingredient identity. What substance is actually present, and in what form?
- Level 2: Proposed mechanism. What do laboratory findings or theoretical explanations suggest might happen?
- Level 3: Human outcome evidence. Did randomised trials show fewer symptomatic, clinically meaningful UTIs?
- Level 4: Product-specific label evidence. Does the retail product clearly identify its ingredient form, amount, serving information and relevant quality details?
A proposed mechanism is the beginning of an evidence question, not the end of one. An explanation about bacterial adhesion does not, by itself, prove that a supplement prevents infection.
What current cranberry evidence shows
The 2023 Cochrane review included 50 randomised controlled trials involving 8,857 people. Across the evidence, cranberry products probably reduced symptomatic, culture-confirmed UTIs in some groups. This included women with recurrent UTIs, children and people susceptible to UTIs after certain clinical interventions.
The review did not find equal benefit for everyone. Results did not support a clear reduction in elderly institutionalised adults, pregnant women, or adults with neuromuscular bladder dysfunction and incomplete bladder emptying. That is why cranberry should be discussed as an evidence-supported option for some groups, not as something that always works.
The review also covered varied cranberry formats. It supports a category-level preventive discussion, but it does not prove that every retail cranberry product will reproduce the same outcome.
The 2024 D-mannose evidence reset
D-mannose became popular because its proposed mechanism is easy to understand and earlier or smaller studies encouraged interest. Many shoppers therefore saw it as a simple non-prescription choice for recurrent urinary support.
A larger placebo-controlled trial published in JAMA Internal Medicine in 2024 deserves greater weight. It enrolled 598 adult women with recurrent UTIs through 99 UK primary-care centres and followed them for six months.
A medically attended UTI occurred in 51.0% of the D-mannose group and 55.7% of the placebo group. The difference was not statistically significant. The trial authors concluded that D-mannose should not be recommended for prophylaxis in women with recurrent UTIs in the primary-care population studied.
This should reduce the confidence of broad consumer recommendations that present D-mannose as an established preventive choice. It should not be stretched into a claim that D-mannose can never have any research use in another population or clinical setting. The correct conclusion is narrower and more useful: in this large primary-care trial, daily D-mannose did not deliver a significant preventive benefit.
A four-question label audit
1. What is the actual ingredient?
For cranberry, look for the species and whether the product uses fruit powder, juice or an extract. For D-mannose, confirm that D-mannose is the named active ingredient. With combination products, identify every active rather than treating the front label as one single substance.
2. What does the amount measure?
A cranberry label may show the physical extract amount, a fresh-fruit equivalent, a PAC amount when explicitly stated, or more than one of these. A D-mannose label usually states the amount of D-mannose per serving. These numbers answer different questions and cannot be ranked by size alone.
3. What evidence relates to that formulation?
Do not assume every cranberry formula matches the juice, powder or extract used in a study. Do not assume every D-mannose powder or capsule reproduces an earlier study simply because the ingredient name is the same.
4. Does the label fit the person?
A supplement decision can be overridden by medicines, kidney disease, a history of stones, pregnancy or breastfeeding, current urinary symptoms, or an existing clinician-managed prevention plan. This is where a pharmacist, GP or qualified health professional can add more value than another front-label comparison.
This article does not select a dose or recommend stacking cranberry with D-mannose.
The Gold Health Unit-Mismatch Check: Why 100,000 mg Is Not a D-Mannose Comparison
The current live page for Gold Health XTR Cranberry 100,000 lists 166.7 mg of North American cranberry extract per capsule. It also states that this is a 600:1 extract and is equivalent to 100,000 mg of fresh cranberry fruit.
Those three statements describe different parts of the formulation:
- 166.7 mg is the physical amount of cranberry extract listed per capsule.
- 600:1 describes the stated extraction relationship.
- 100,000 mg is the stated fresh-fruit equivalent.
The 100,000 mg figure is not the physical capsule weight. It is not the physical extract amount. It is not a PAC amount. It is also not a number that can be compared directly with grams of D-mannose.
The live page says the product is standardised for PACs, but the visible page does not state a PAC amount in milligrams. Standardisation can describe consistency to a specification. It does not reveal a PAC dose unless an amount is explicitly stated, and it does not guarantee a preventive outcome.
D-mannose labels generally state an amount of a different ingredient per serving. The useful comparison is therefore evidence, ingredient identity, label transparency, serving information and individual suitability. It is not the largest number on the page.
For symptom-free maintenance, the current online page lists one capsule daily with food or as professionally prescribed. The page also contains separate wording about increasing intake when a UTI is suspected. This article does not reproduce or endorse that symptom-related increase as consumer advice. New or worsening symptoms require healthcare assessment rather than a larger cranberry amount.
The current online cautions say to consult a doctor before use with warfarin or other blood-thinning medicines, not to use with kidney disease, to seek medical advice with a history of oxalate kidney stones, and to use only under professional supervision during pregnancy or breastfeeding. The page also says persistent or worsening symptoms require professional review and blood in urine needs immediate attention.
Online wording and physical packs can change at different times. Follow the current approved label, and verify the current physical pack and approved directions immediately before publication or use if the webpage and pack differ.
When suitability vetoes the supplement comparison
Stop comparing products and seek professional review when any of the following applies:
- new burning or pain when urinating
- fever, shaking or feeling acutely unwell
- back or side pain
- blood in urine
- persistent or worsening urinary symptoms
- pregnancy
- kidney disease
- a history of oxalate kidney stones
- warfarin or another blood-thinning medicine
- recurrent symptoms without a clinician-reviewed prevention plan
- uncertainty about combining cranberry with D-mannose, medicines or other supplements
For a more detailed age-specific pathway, medicine checks and caregiver considerations, read Cranberry Supplements for Older Adults. For the broader category context, the Urinary Tract Support collection provides a same-brand hub, but it is not a substitute for assessment when symptoms are present.
Active symptoms change the next step
A supplement comparison is for symptom-free preventive discussions. New or worsening urinary symptoms need healthcare assessment rather than a larger supplement amount. Neither cranberry nor D-mannose replaces prescribed treatment or professional care.
Frequently asked questions
Is cranberry better than D-mannose?
Not for every person or every setting. Cranberry currently has stronger preventive evidence for some groups, including women with recurrent UTIs, while the large 2024 primary-care D-mannose trial found no significant benefit in the population studied. Suitability, formulation and current symptoms still matter.
Do cranberry and D-mannose work in the same way?
No. They are different ingredients, although both are often discussed in relation to bacterial adhesion. A proposed mechanism is not the same as proof that a product reduces clinically meaningful UTIs.
Which has stronger evidence for recurrent UTI prevention?
Cranberry has stronger current human evidence for women with recurrent UTIs. The 2023 Cochrane review found probable benefit in this group, while the 2024 D-mannose trial in women with recurrent UTIs in primary care did not find a statistically significant preventive benefit.
Is D-mannose a sugar?
Yes. D-mannose is a simple sugar related to glucose. Its identity as a sugar does not by itself show whether it produces a meaningful preventive outcome.
What are PACs in cranberry?
PACs are proanthocyanidins, plant compounds found in cranberry. They are studied partly because of a proposed effect on bacterial adhesion, but PAC wording alone does not prove that a particular supplement prevents UTIs.
Can cranberry and D-mannose be taken together?
There is no good basis for saying that combining them is proven to work better. Check with a pharmacist, GP or qualified health professional before combining them, especially if you take medicines, have kidney concerns, are pregnant or breastfeeding, or already follow a clinician-managed prevention plan.
Can either option treat an active UTI?
No. Cranberry and D-mannose are not treatments for an active UTI and should not replace assessment or prescribed care. New or worsening urinary symptoms need healthcare advice rather than a larger supplement amount.
How should I compare cranberry and D-mannose label amounts?
First identify what each number measures. A cranberry extract amount, fresh-fruit equivalent or stated PAC amount is not directly comparable with grams of D-mannose, so compare evidence, formulation details, serving information and suitability instead.
Does standardised for PACs state the PAC dose?
No. It indicates that PAC content is controlled to a specification, but it does not state the PAC amount unless the label gives a number in milligrams or another defined unit. Do not calculate or assume a PAC dose from a fresh-fruit equivalent.
Who should check with a health professional before using cranberry?
Check first if you take warfarin or another blood-thinning medicine, have kidney disease or a history of oxalate kidney stones, or are pregnant or breastfeeding. Also seek advice for recurrent symptoms, blood in urine, persistent or worsening symptoms, or uncertainty about combining supplements with medicines.
Evidence-led next step
For a symptom-free daily support discussion, cranberry currently has stronger evidence than D-mannose in the populations described above. The practical next step is to read the formulation and cautions carefully, then check suitability with a pharmacist, GP or qualified health professional when medicines, kidney factors, pregnancy or recurrent symptoms are involved.
References
- Cochrane: Cranberries for preventing urinary tract infections, 2023 update
- JAMA Internal Medicine: D-mannose for prevention of recurrent urinary tract infection among women, 2024
- National Center for Complementary and Integrative Health: Cranberry usefulness and safety
This article provides general information only. It does not diagnose, treat or replace advice from a qualified health professional.
